1063 related articles for article (PubMed ID: 33852780)
1. Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ
N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780
[TBL] [Abstract][Full Text] [Related]
2. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
[TBL] [Abstract][Full Text] [Related]
3. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression.
Brunoni AR; Moffa AH; Sampaio-Junior B; Borrione L; Moreno ML; Fernandes RA; Veronezi BP; Nogueira BS; Aparicio LVM; Razza LB; Chamorro R; Tort LC; Fraguas R; Lotufo PA; Gattaz WF; Fregni F; Benseñor IM;
N Engl J Med; 2017 Jun; 376(26):2523-2533. PubMed ID: 28657871
[TBL] [Abstract][Full Text] [Related]
4. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
6. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
[TBL] [Abstract][Full Text] [Related]
7. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
Brown ES; Howard C; Khan DA; Carmody TJ
Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
9. Increased global integration in the brain after psilocybin therapy for depression.
Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
[TBL] [Abstract][Full Text] [Related]
10. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM; Aaronson ST; Alvarez O; Arden PC; Baker A; Bennett JC; Bird C; Blom RE; Brennan C; Brusch D; Burke L; Campbell-Coker K; Carhart-Harris R; Cattell J; Daniel A; DeBattista C; Dunlop BW; Eisen K; Feifel D; Forbes M; Haumann HM; Hellerstein DJ; Hoppe AI; Husain MI; Jelen LA; Kamphuis J; Kawasaki J; Kelly JR; Key RE; Kishon R; Knatz Peck S; Knight G; Koolen MHB; Lean M; Licht RW; Maples-Keller JL; Mars J; Marwood L; McElhiney MC; Miller TL; Mirow A; Mistry S; Mletzko-Crowe T; Modlin LN; Nielsen RE; Nielson EM; Offerhaus SR; O'Keane V; Páleníček T; Printz D; Rademaker MC; van Reemst A; Reinholdt F; Repantis D; Rucker J; Rudow S; Ruffell S; Rush AJ; Schoevers RA; Seynaeve M; Shao S; Soares JC; Somers M; Stansfield SC; Sterling D; Strockis A; Tsai J; Visser L; Wahba M; Williams S; Young AH; Ywema P; Zisook S; Malievskaia E
N Engl J Med; 2022 Nov; 387(18):1637-1648. PubMed ID: 36322843
[TBL] [Abstract][Full Text] [Related]
11. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder.
Brown ES; Sayed N; Van Enkevort E; Kulikova A; Nakamura A; Khan DA; Ivleva EI; Sunderajan P; Bender BG; Holmes T
J Allergy Clin Immunol Pract; 2018; 6(5):1604-1612. PubMed ID: 29409976
[TBL] [Abstract][Full Text] [Related]
13. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
[TBL] [Abstract][Full Text] [Related]
14. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
[TBL] [Abstract][Full Text] [Related]
15. Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Panwar A; Rieke K; Burke WJ; Sayles H; Lydiatt WM;
JAMA Otolaryngol Head Neck Surg; 2018 Nov; 144(11):1004-1010. PubMed ID: 30286230
[TBL] [Abstract][Full Text] [Related]
16. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G
JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T
Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
19. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
[TBL] [Abstract][Full Text] [Related]
20. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
Favré P
Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
